ALK Abello’s Itulazax gets European approval for children

Denmark-based allergy immunotherapy specialist ALK Abello (ALKB. DC) today announced that its Itulazax (tree pollen sublingual allergy immunotherapy tablet) has been approved by the European regulator for treatment of young children and adolescents aged five to 17.

First market introductions are expected to follow in the coming months ahead of the 2025/2026 initiation season for new patients starting treatment on     pollen allergy tablets, said ALK Abello, whose shares edged up 2.4% to 147.60 kroner on the news.

Executive vice president of R&D, Dr Henriette Mersebach, says: “We are very pleased with the European health authorities' approval which allows us to provide this important treatment option to children and adolescents whose lives are impaired by uncontrolled tree pollen-induced respiratory allergy. Today’s approval marks another significant milestone in our continuous efforts to make our respiratory tablets available to all age groups in all relevant markets."